Advanced Triple Negative Breast Cancer clinical trials

Explore recruiting advanced triple negative breast cancer clinical trials.

Recruiting advanced triple negative breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Triple Negative Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer “TRIFOUR study”

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVALUMAB/NAB-PACLITAXEL: THE ATRiBRAVE TRIAL

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumab as first-line treatment in advanced triple negative breast cancer

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

ALTER : A Phase 2, Multicenter, Randomized, Open-label trial assessing sacituzumab-govitecan and trastuzumab-deruxtecan combinaison in an ALTERnating regimen for patients with metastatic or locally advanced Her2-low triple-negative breast Cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Triple Negative Breast Cancer trials by city

Advanced Triple Negative Breast Cancer in Toronto Advanced Triple Negative Breast Cancer in Vancouver Advanced Triple Negative Breast Cancer in Montreal Advanced Triple Negative Breast Cancer in Calgary Advanced Triple Negative Breast Cancer in Edmonton Advanced Triple Negative Breast Cancer in Ottawa Advanced Triple Negative Breast Cancer in Winnipeg Advanced Triple Negative Breast Cancer in Quebec City Advanced Triple Negative Breast Cancer in Hamilton Advanced Triple Negative Breast Cancer in Kitchener Advanced Triple Negative Breast Cancer in London Advanced Triple Negative Breast Cancer in Halifax Advanced Triple Negative Breast Cancer in New York Advanced Triple Negative Breast Cancer in Los Angeles Advanced Triple Negative Breast Cancer in Chicago Advanced Triple Negative Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease